BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Bespoke Consortium Born to Bring Gene Therapy to Rare Diseases

  Collaboration is key to faster breakthroughs. The NIH, FDA, and 15 private organizations have announced they are joining forces for the sake of the 30 million Americans suffering from a rare disease.

  October 28, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Drug Development

  Texas A&M Drug Shows Promise Against Multiple Respiratory Infections

  Researchers believe the drug PUL-042 may work against COVID-19 and other respiratory infections, including all existing and future variants of SARS-CoV-2.

  October 28, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Research Roundup: Amino Acids Might Fend Off Dementia and Alzheimer’s and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  October 28, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Career Advice

  How Introverts and Extroverts Approach the Same Job Differently

  Differing skillsets mean that extroverts and introverts will usually approach the same job differently. Here is how each of them do it.

  October 28, 2021

   · 

  2 min read

   · 

  Brandi Marcene
• 

  Business

  Alnylam’s Maraganore Stepping Down; Harpoon Taps New CEO

  Alnylam Chief Executive Officer Dr. John Maraganore, who has guided the company’s RNAi therapies from concept to commercialization, is handing over the reins of the company at the end of the year.

  October 28, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Positive Results in Hand, AbbVie Eyes Potential Approval for Parkinson’s Treatment

  AbbVie’s experimental subcutaneous Parkinson’s disease drug ABBV-951 hit the mark in a 12-week Phase III study in patients with an advanced form of the disease.

  October 28, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  SynaptixBio Formed to Tackle One of the World’s Rarest Diseases

  Although the literature suggests this condition may affect 200 people globally, Williams and his team think the numbers are higher.

  October 28, 2021

   · 

  4 min read

   · 

  Gail Dutton
• 

  FDA

  50 Million J&J Vaccine Doses Found Idle in Baltimore Plant

  Emergent BioSolutions, the manufacturer responsible for the doses in question, is reportedly just waiting for the U.S. FDA’s signal to start shipping the vaccines.

  October 28, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Career Advice

  Should I Stay or Should I Go? Deciding if it’s the Right Time to Job Search

  If you’ve been getting the itch to job search but you aren’t sure if you should, here are some reasons to possibly leave a job that might help you decide if you should stay or if you should go.

  October 28, 2021

   · 

  4 min read

   · 

  Hannah Harshman
• 

  Policy

  Novartis Under New DOJ Scrutiny Over Potential Kickback Allegations

  Novartis is the subject of a DOJ inquiry over the company’s marketing and pricing of Entresto over the past five years, receiving a Civil Investigative Demand from the government.

  October 28, 2021

   · 

  3 min read

   · 

  Alex Keown